NYMOX PHARMACEUTICAL CORP
NYMXF evidence brief
What we can confirm
- Market Cap:
- $21K
What it means
What to watch
Prepared research question
What matters most for NYMXF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NYMXF
NYMOX PHARMACEUTICAL CORP is a Bahamian biopharmaceutical company developing its drug candidate NX-1207 (fexapotide triflutate) for benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer, with no current product sales and a history of net losses.
Key risk: No revenue and net losses
Market Cap
$21K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2024.
NYMOX PHARMACEUTICAL CORP is a Bahamian biopharmaceutical company developing its drug candidate NX-1207 (fexapotide triflutate) for benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer, with no current product sales and a history of net losses.
- NYMOX is focused on developing NX-1207 (fexapotide triflutate) for BPH and low-grade localized prostate cancer [sec · filed 2025-06-03].
- Two long-term studies (NX02-0017 and NX02-0018) of fexapotide for BPH met their pre-specified primary endpoint of long-term symptomatic benefit superior to placebo, with an excellent safety profile [sec · filed 2025-06-03].
- The company filed Marketing Authorization Applications (MAAs) in Denmark and the UK; the UK MAA remains under consideration [sec · filed 2025-06-03].
- Revenues from product sales were nil for the years ended December 31, 2023 and 2022 [sec · filed 2024-08-29].
- Net loss was $8,844,758 for the year ended December 31, 2023, compared to $6,575,922 for 2022 [sec · filed 2024-08-29].
What works
- NX-1207 demonstrated statistically significant long-term symptomatic benefit superior to placebo in two clinical studies with an excellent safety profile [sec · filed 2025-06-03].
- The company has an extensive patent portfolio covering its investigational drug and other therapeutic indications, including U.S. and global patent rights for statin drugs in Alzheimer's disease [sec · filed 2024-08-29].
- MAAs have been filed in Denmark and the UK, indicating progress toward potential regulatory approval [sec · filed 2025-06-03].
What to weigh
- The company has no current product revenues; revenues from sales of goods were nil for 2023 and 2022 [sec · filed 2024-08-29].
- Net losses have been increasing, from $6,575,922 in 2022 to $8,844,758 in 2023 [sec · filed 2024-08-29].
- As of December 31, 2023, the company had negative working capital of $3,175,000 and stated it cannot say when, if ever, it will become profitable [sec · filed 2024-08-29].
- The company expects to require additional funds to continue as a going concern and may need to seek equity or other financing [sec · filed 2025-06-03].
From the filings
Quoted directly from source documents.
NX-1207 met its primary endpoint in two long-term studies
“NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo.”
SEC filings · June 3, 2025
No product revenues in recent years
“Revenues from sales of goods were nil for the year ended December 31, 2023 and 2022.”
SEC filings · August 29, 2024
Net loss increased in 2023
“Net losses were $8,844,758, or $0.10 per share, for the year ended December 31, 2023, compared to $6,575,922, or $0.07 per share, for the year ended December 31, 2022.”
SEC filings · August 29, 2024
Negative working capital as of end of 2023
“As of December 31, 2023, we had negative working capital of $3,175,000.”
SEC filings · August 29, 2024
Risks & what to watch (3)›
Key risks
- No revenue and net losses — Nil product sales and increasing net losses ($8.8M in 2023) with negative working capital of $3.2M [sec · filed 2024-08-29].
- Regulatory approval uncertainty — MAAs filed in Denmark and UK; UK MAA still under consideration with no guarantee of approval [sec · filed 2025-06-03].
- Going concern and financing risk — Company states it will require additional funds to continue operations and may need to seek equity or other financing [sec · filed 2025-06-03].
What to watch
- Outcome of the UK MAA for NX-1207, which remains under consideration [sec · filed 2025-06-03].
- Any updates on regulatory meetings or filings in other jurisdictions [sec · filed 2025-06-03].
- Company's ability to secure additional financing to sustain operations [sec · filed 2025-06-03].
- Future clinical or regulatory milestones for NX-1207 in BPH or prostate cancer [sec · filed 2025-06-03].
Sources: SEC filings · Generated September 25, 2026 · How we verify sources →
Run NYMOX PHARMACEUTICAL CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NYMOX PHARMACEUTICAL CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$2K
| Holder | Shares | Value |
|---|---|---|
| first citizens financial corp | 35,100 | $2K |
Short Interest
as of Apr 22, 2026- % of float
- 4.7%
- Days to cover
- 59.7
- Shares short
- 2,033,620
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NYMXF short interestFrequently asked questions
What is the AI investment thesis for NYMOX PHARMACEUTICAL CORP?
NYMOX PHARMACEUTICAL CORP is a Bahamian biopharmaceutical company developing its drug candidate NX-1207 (fexapotide triflutate) for benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer, with no current product sales and a history of net losses.
Who is the CEO of NYMOX PHARMACEUTICAL CORP?
Dr. Paul Averback DABP, M.D. is the chief executive officer of NYMOX PHARMACEUTICAL CORP (NYMXF).
Where is NYMOX PHARMACEUTICAL CORP headquartered?
NYMOX PHARMACEUTICAL CORP (NYMXF) is headquartered in Nassau, Bahamas.
What therapeutic areas does NYMOX PHARMACEUTICAL CORP focus on?
NYMOX PHARMACEUTICAL CORP develops therapies across Oncology, Rare Disease, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Dermatology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.